On October 16, Humana fell 3.14% in Regular Trading, trading at $418.6 per share, with turnover of $66.7241 million.

The most recent catalyst was a new analyst action: William O'Neil initiated coverage on Humana with a Buy rating. Despite that supportive call, the stock moved lower during the session.

Recent analyst sentiment has remained broadly constructive. Consensus tracked by FactSet showed an average overweight rating and a mean price target of $460.46. Earlier in the week, Mizuho raised its target price to $495, while UBS also lifted its target to $495. Earlier support for the shares also came after Humana reaffirmed full-year adjusted EPS guidance of at least $9 and said 95% of its Medicare Advantage members are enrolled in plans rated at least four stars for 2027.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)